{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:01:01Z","timestamp":1787162461656,"version":"build-2736575974"},"reference-count":19,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016477","name":"CareDx Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016477","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019399","name":"Eurofins Viracor BioPharma Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.transproceed.2025.10.023","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T12:12:58Z","timestamp":1761912778000},"page":"1920-1924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunosuppression Minimization in Belatacept-Treated Kidney Transplant Recipients Guided by Combined Cell-Free DNA and Blood Gene Expression Monitoring"],"prefix":"10.1016","volume":"57","author":[{"given":"Thomas","family":"Vanhove","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wojciechowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Gilligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2025.10.023_bib0001","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1681\/ASN.2016091034","article-title":"Cell-Free DNA and active rejection in kidney allografts","volume":"28","author":"Bloom","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2025.10.023_bib0002","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/ajt.15142","article-title":"Diagnostic application of kidney allograft-derived absolute cell-free DNA levels during transplant dysfunction","volume":"19","author":"Whitlam","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2025.10.023_bib0003","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1111\/ajt.15289","article-title":"Early clinical experience using donor-derived cell-free DNA to detect rejection in kidney transplant recipients","volume":"19","author":"Huang","year":"2019","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.transproceed.2025.10.023_bib0004","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/ndt\/gfz091","article-title":"The use of plasma donor-derived, cell-free DNA to monitor acute rejection after kidney transplantation","volume":"35","author":"Gielis","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1016\/j.transproceed.2025.10.023_bib0005","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/TP.0000000000004482","article-title":"Understanding donor-derived cell-free DNA in kidney transplantation: an overview and case-based guide for clinicians","volume":"107","author":"Graver","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2025.10.023_bib0006","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1681\/ASN.2021091191","article-title":"The trifecta study: comparing plasma levels of donor-derived cell-free DNA with the molecular phenotype of kidney transplant biopsies","volume":"33","author":"Halloran","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2025.10.023_bib0007","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.2215\/CJN.05530421","article-title":"Combining blood gene expression and cellfree DNA to diagnose subclinical rejection in kidney transplant recipients","volume":"16","author":"Park","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2025.10.023_bib0008","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/TP.0000000000003838","article-title":"Correlation of donor-derived cell-free DNA with histology and molecular diagnoses of kidney transplant biopsies","volume":"106","author":"Gupta","year":"2022","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.transproceed.2025.10.023_bib0009","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1111\/ajt.15416","article-title":"Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: results from a prospective observational study","volume":"19","author":"Oellerich","year":"2019","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.transproceed.2025.10.023_bib0010","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/ajt.15011","article-title":"Development and clinical validity of a novel blood-based molecular biomarker for subclinical acute rejection following kidney transplant","volume":"19","author":"Friedewald","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2025.10.023_bib0011","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.transproceed.2019.01.054","article-title":"Application of TruGraf v1: a novel molecular biomarker for managing kidney transplant recipients with stable renal function","volume":"51","author":"Marsh","year":"2019","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2025.10.023_bib0012","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.kint.2021.11.034","article-title":"Clinical outcomes from the assessing donor-derived cell-free DNA monitoring insights of kidney allografts with longitudinal surveillance (ADMIRAL) study","volume":"101","author":"Bu","year":"2022","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.transproceed.2025.10.023_bib0013","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/jcm8010019","article-title":"Optimizing detection of kidney transplant injury by assessment of donor-derived cell-free DNA via massively multiplex PCR","volume":"8","author":"Sigdel","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.transproceed.2025.10.023_bib0014","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.transproceed.2022.12.003","article-title":"Reduction in maintenance immunosuppression in kidney transplant recipients with stable donor-derived cell-free DNA measurements: a case series","volume":"55","author":"Lum","year":"2023","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2025.10.023_bib0015","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1600-6143.2011.03914.x","article-title":"Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys","volume":"12","author":"Pestana","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2025.10.023_bib0016","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/ajt.14721","article-title":"De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies","volume":"18","author":"Bray","year":"2018","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg"},{"key":"10.1016\/j.transproceed.2025.10.023_bib0017","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1111\/ajt.16121","article-title":"Kidney transplantation using alemtuzumab, belatacept, and sirolimus: Five-year follow-up","volume":"20","author":"Schmitz","year":"2020","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg"},{"key":"10.1016\/j.transproceed.2025.10.023_bib0018","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/ajt.12712","article-title":"Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors","volume":"14","author":"Kirk","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2025.10.023_bib0019","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1111\/ajt.16538","article-title":"Every 2-month belatacept maintenance therapy in kidney transplant recipients greater than 1-year posttransplant: a randomized, noninferiority trial","volume":"21","author":"Badell","year":"2021","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113452500538X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113452500538X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:23:43Z","timestamp":1780820623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004113452500538X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S004113452500538X"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2025.10.023","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosuppression Minimization in Belatacept-Treated Kidney Transplant Recipients Guided by Combined Cell-Free DNA and Blood Gene Expression Monitoring","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2025.10.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}